NDA 021920 · Bionpharma
Naproxen Sodium
Naproxen Sodium · Oral
Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Feb 17, 2006
Approved uses
1
Original approval plus efficacy supplements
Registered trials
356
90 Phase 3, 11 recruiting
FAERS reports
66,594
27,369 serious, 5,059 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 5, 2026.
Uses temporarily relieves minor aches and pains due to: backache muscular aches minor pain of arthritis menstrual cramps headache toothache the common cold temporarily reduces fever
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- NAPROXEN SODIUM · NAPROXEN SODIUM EQ 200MG BASE · CAPSULE, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Naproxen" as an intervention, any sponsor and status, largest first.
- Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or NaproxenPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00346216 · 24,081 participants · Start Oct 4, 2006 · Primary completion Apr 12, 2016
Drug: celecoxib; Ibuprofen and 1 more · For: Arthritis, Rheumatoid
Sites: Alabaster, Alabama; Bessemer, Alabama; Birmingham, Alabama · 1,066 sites in all
- The Standard Care Versus Celecoxib Outcome TrialPivotal-lookingCompleted
University of DundeeAcademic, hospital or other
NCT00447759 · 7,297 participants · Start Jun 2007 · Primary completion Aug 2015
Drug: Celecoxib; Diclofenac · For: Osteoarthritis; Rheumatoid Arthritis
Sites: Odense, Denmark; Zeist, Netherlands; Aberdeen, United Kingdom · 10 sites in all
- A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or HipPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03161093 · 3,307 participants · Start Aug 17, 2017 · Primary completion Sep 9, 2019
Drug: Fasinumab; Naproxen and 2 more · For: Osteoarthritis, Knee; Osteoarthritis, Hip
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 139 sites in all
- Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or KneePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02528188 · 3,021 participants · Start Jul 21, 2015 · Primary completion Oct 5, 2018
Drug: NSAID; Tanezumab 2.5 mg and 1 more · For: Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 507 sites in all
- Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or HipPivotal-lookingTerminated
PfizerPfizer (PFE)
NCT00809354 · 2,720 participants · Start Feb 12, 2009 · Primary completion Oct 28, 2010
Drug: NSAID; tanezumab and 5 more · For: Osteoarthritis; Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 333 sites in all
- Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)Pivotal-lookingCompleted
Seattle Institute for Biomedical and Clinical ResearchAcademic, hospital or other
NCT00007189 · 2,625 participants · Start Jan 2001 · Primary completion May 2007
Drug: Naproxen Sodium (Aleve); Celecoxib (Celebrex) · For: Alzheimer Disease
Sites: Sun City, Arizona; Tampa, Florida; Baltimore, Maryland · 6 sites in all
- Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of MigrainePivotal-lookingCompleted
Eurofarma Laboratorios S.A.Industry
NCT04384367 · 2,068 participants · Start Dec 30, 2022 · Primary completion Oct 30, 2024
Drug: Rizatriptan 10 mg + Naproxen 550mg; Maxalt 10Mg Tablet and 2 more · For: Migraine
Sites: São Paulo, Brazil · 2 sites in all
- Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With GoutPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT02139046 · 1,790 participants · Start Apr 2014 · Primary completion Nov 2015
Drug: Febuxostat IR; Febuxostat XR and 4 more · For: Gout
Sites: Binghamton, Alabama; Birmingham, Alabama; Huntsville, Alabama · 192 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective11,083
- fatigue5,089
- product use issue4,788
- pain4,754
- nausea4,276
- arthralgia4,097
- headache4,062
- off label use3,990
- dizziness3,951
- diarrhoea3,946
- rash3,562
- vomiting3,466
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 644 |
| 2005 | 773 |
| 2006 | 633 |
| 2007 | 659 |
| 2008 | 3,280 |
| 2009 | 1,851 |
| 2010 | 786 |
| 2011 | 1,013 |
| 2012 | 1,808 |
| 2013 | 1,570 |
| 2014 | 3,690 |
| 2015 | 7,074 |
| 2016 | 6,846 |
| 2017 | 5,779 |
| 2018 | 4,834 |
| 2019 | 4,632 |
| 2020 | 3,587 |
| 2021 | 3,017 |
| 2022 | 2,928 |
| 2023 | 2,813 |
| 2024 | 3,527 |
| 2025 | 3,243 |
| 2026 | 1,605 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Naproxen Sodium (Naproxen Sodium)
2024 spending
$2.8M
Beneficiaries
38,101
69,827 claims
Per beneficiary
$73
$0.69 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,598,959 |
| 2021 | $3,694,074 |
| 2022 | $3,258,596 |
| 2023 | $5,373,172 |
| 2024 | $2,780,942 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Nissen SE, Yeomans ND, Solomon DH, et al. · N Engl J Med 2016 · Multicenter Study, Randomized Controlled Trial
- A systematic review and meta-analysis of naproxen for prevention heterotopic ossification after hip surgery.
Zhang AH, Chen X, Zhao QX, et al. · Medicine (Baltimore) 2019 · Comparative Study, Meta-Analysis
- Naproxen in dysmenorrhoea.
Pauls F · Lancet 1978 · Clinical Trial, Letter
- Naproxen chemoprevention induces proliferation of cytotoxic lymphocytes in Lynch Syndrome colorectal mucosa.
Bowen CM, Deng N, Reyes-Uribe L, et al. · Front Immunol 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Herbal formulation "turmeric extract, black pepper, and ginger" versus Naproxen for chronic knee osteoarthritis: A randomized, double-blind, controlled clinical trial.
Heidari-Beni M, Moravejolahkami AR, Gorgian P, et al. · Phytother Res 2020 · Randomized Controlled Trial
- Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults.
Law S, Derry S, Moore RA · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Bionpharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.